Product category:
Pharmaceutical Processing News
News Release from: Frost and Sullivan
Edited by the Processingtalk Editorial
Team on 14 March 2003
Leadership and innovation awards
A dual honour: Roche Diagnostics receives two Frost and Sullivan awards for pioneering excellence in the European in vitro diagnostics industry
Roche Diagnostics exceptional performance in 2002 was today recognised by international growth consultants Frost and Sullivan, who honoured the company with two prestigious market engineering awards Roche received the leadership award for the European market nucleic acid-based amplification kits
This article was originally published on Processingtalk on 7 Feb 2003 at 8.00am (UK)
Related stories
The HIV/AIDS Therapies Market
While antiretroviral drugs in existing categories continue to be the mainstay of the HIV/AIDS therapies market in the United States, the development of new drugs offers exciting growth prospects
The European breast cancer pharmaceuticals market
The quest for a breast cancer wonder drug, and improved survival rates, continue to pump up business in the breast cancer pharmaceutical industry
It also won the product differentiation innovation award for the European cardiac risk assessment markers market.
"At Roche Diagnostics we are proud to have won these awards for proBNP and PCR.
They will be an incentive for all of us to bring further innovations for the in-vitro diagnostics market This will help our customers to improve the quality and safety of their services", says Manfred Baier, Head of the Business Area Lab Network at Roche Diagnostics.
Further reading
Proteomics sample preparations markets
Integrated, customised, and validated research solutions for proteomics analyses and drug discoveries will fuel growth in the sample preparations market, according to the latest market resaerch report
Portfolio management in pharmaceutical market
Portfolio management carves a niche for itself in the resource-constrained pharmaceutical market, based on the need to identify and prioritise the most profitable projects in the R and D pipeline
Pharma rethinks traditional product marketing
A resurgent disease management sector will compel pharmaceutical companies to market products as constituents of packages of care, re-directing their sales efforts towards planners rather than doctors
As the first company to enter the natriuretic peptide (NP) market with a laboratory-based test, offering the pro-brain natriuretic peptide (proBNP) assay on its Elecsys system, Roche Diagnostics is a worthy recipient of the product differentiation innovation award.
Prior to this groundbreaking product development in 2002, no other laboratory-based NP test was commercially available.
A recent end-user study has shown that Roche Diagnostics is set to make immediate gains due to the wide existing base of Elecsys analyser machines in hospital laboratories.
ProBNP is set to become an essential tool to combat cardiac heart failure.
It is anticipated to have amongst the highest rates of growth, expanding into the fourth largest cardiac risk markers market as early as 2005.
"Since Roche is the exclusive licence holder to the rights to proBNP testing in the cardiac risk assessment field, any company looking to enter this market will have to in-license the technology from Roche.
For the time being, however, no new market entrants are expected and Roche is poised to maintain its leadership position in the near term," says Mr Wong.
The product differentiation innovation award is, therefore, presented to Roche Diagnostics in acknowledgement of its proven ability to develop and advance products with more innovative capabilities than competing vendors/products.
The leadership award was awarded to Roche Diagnostics for having successfully leveraged its patented polymerase chain reaction (PCR) technology into the "gold standard" for nucleic acid amplification technology.
"As the principle holder of the patents for the PCR technology, Roche Diagnostics earns royalties from all licensed competitors marketing PCR-based products, including kits and consumables.
As a result, Roche participates significantly in both clinical and research markets," explains Frost and Sullivan Analyst, Alex Wong.
"We remain deeply committed to developing innovative molecular-based diagnostics tests and PCR automated testing platforms," stated Heiner Dreismann, Head of Roche Molecular Systens, the Roche Diagnostics business area which has made PCR the leading nucleic acid amplification technology in the world.
The company today is market leader in the European clinical diagnostic kit market.
Based on its proprietary technology, Roche is poised to maintain its lead in the European nucleic acid-based amplification kits market, forecast to be worth over $575 million by 2006.
It is the only participant in the clinical nucleic acid-based kits market with a comprehensive portfolio that spans over six principal virus- and bacteria- borne diseases found in western Europe, with Human Papillomavirus (HCV) being the most recent addition to its armoury.
"In addition to the qualitative products, Roche leads the way in the quantitation market, whereby its outstanding AMPLICOR range of monitoring assays for HIV, HCV, and HBV has permitted the surveillance and prognosis of these viral diseases," adds Mr Wong.
The leadership award, therefore, honours Roche Diagnostics for having been at the frontline of market and technology developments as well as for having consistently outperformed its competitors in terms of market share and revenue growth rate.
• Frost and Sullivan: contact details and other news
• Email this article to a colleague
• Register for the free Processingtalk email newsletter
• Processingtalk Home Page
Search the Pro-Talk network of sites
